Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals

Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production

Fineline Cube Mar 12, 2025

US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a...

Company Drug

Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa

Fineline Cube Mar 12, 2025

Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...

Company

Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results

Fineline Cube Mar 12, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...

Company Deals

Ono Pharmaceutical Licenses Ionis’ Sapablursen for Global Development in Polycythemia Vera

Fineline Cube Mar 12, 2025

Japan-based Ono Pharmaceutical Co., Ltd. (TYO: 4528) announced an agreement with Ionis Pharmaceuticals, Inc. to...

Company Deals

Boehringer Ingelheim Launches One Medicine Platform with Veeva’s Development Cloud

Fineline Cube Mar 12, 2025

German pharmaceutical giant Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) announced the successful launch of...

Company Drug

Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients

Fineline Cube Mar 12, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...

Company Deals

MindRank Ltd Receives FDA Clearance for MRANK-106 Clinical Study in Solid Tumors

Fineline Cube Mar 12, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced receiving clearance from the US Food...

Company Drug

AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine

Fineline Cube Mar 12, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...

Company Deals

TowardPi Medical Secures RMB500 Million in Series E Round for Ophthalmic Equipment Expansion

Fineline Cube Mar 12, 2025

China-based TowardPi (Beijing) Medical Technology Ltd, a leading ophthalmology equipment R&D company, has reportedly secured...

Company Deals

WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation

Fineline Cube Mar 12, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...

Company Drug

Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss

Fineline Cube Mar 12, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...

Company Drug

AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment

Fineline Cube Mar 11, 2025

UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...

Company Medical Device

Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment

Fineline Cube Mar 11, 2025

Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing...

Company

Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth

Fineline Cube Mar 11, 2025

China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy...

Company Deals

Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out

Fineline Cube Mar 11, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ)...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC

Fineline Cube Mar 11, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...

Company

Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban

Fineline Cube Mar 11, 2025

US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued...

Company Drug

Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment

Fineline Cube Mar 11, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...

Company Digital

Hansoh Pharmaceutical’s Ameile Wins New NMPA Approval for Advanced NSCLC Treatment

Fineline Cube Mar 11, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced receiving another indication approval from the...

Company Deals

IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture

Fineline Cube Mar 11, 2025

China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a...

Posts pagination

1 … 241 242 243 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.